Contiguous Overlapping Peptides for House Dust Mite Allergy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for house dust mite allergy, such as specific immunotherapy (SIT), are lengthy and often accompanied by side effects, necessitating a more efficient and safer alternative that can rapidly reduce allergic symptoms.
Innovation Solution
The development of contiguous overlapping peptides (COPs) derived from the major allergens Der p 1 and Der p 2, which include the complete sequence of these allergens, are used to treat house dust mite allergies. These peptides are administered in a shorter regimen, reducing IgE binding and eliciting an immune response without forming the original allergen's three-dimensional structure, thereby minimizing allergic reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional specific immunotherapy (SIT) is used to treat house dust mite allergy, then the treatment can induce immune response and reduce allergic symptoms, but the treatment period is lengthy and side effects occur
Solution Approach 1:
The patent segments the major allergens Der p 1 and Der p 2 into multiple contiguous overlapping peptides (COPs). Each peptide covers a specific region of the allergen sequence, and together they comprehensively cover the entire allergen structure. This segmentation allows the immune system to respond to multiple epitopes simultaneously, accelerating the immunotherapy process while maintaining effectiveness and reducing treatment duration.
Solution Approach 2:
The patent changes the molecular parameters of the allergens by using truncated peptide sequences instead of full-length proteins. The COPs are designed to cover 70-90% of the allergen sequence while excluding specific regions that trigger strong IgE-mediated allergic reactions. This parameter change enables faster immune response induction with reduced side effects.
2Reliability
If traditional specific immunotherapy (SIT) is used to treat house dust mite allergy, then the treatment can induce immune response and reduce allergic symptoms, but side effects such as allergic reactions occur
Solution Approach 1:
The patent extracts specific regions from the full-length allergen sequences that are responsible for triggering strong IgE-mediated allergic reactions. By designing COPs that cover 70-90% of the allergen sequence while deliberately excluding highly allergenic regions, the treatment maintains immunogenicity while reducing side effects. This extraction approach allows effective allergy treatment with minimized harmful reactions.
Solution Approach 2:
The patent converts the harmful IgE-mediated allergic response into a beneficial immune response by using COPs that stimulate T-cell mediated immunity rather than IgE production. The truncated peptide sequences are designed to induce protective immune responses (IgG4 antibodies and T-regulatory cell activation) without triggering the harmful IgE pathway, thus converting potential harm into therapeutic benefit.
3Reliability
If full-length allergens are used in immunotherapy, then complete immune response can be induced, but strong IgE binding and anaphylactic shock risk occur
Solution Approach 1:
The patent segments full-length allergens into multiple overlapping peptides, each covering a specific region. This segmentation prevents the formation of complete three-dimensional allergen structures that would bind IgE antibodies, while still presenting multiple linear epitopes to the immune system. The result is comprehensive immune response induction without IgE-mediated anaphylactic shock risk.
Solution Approach 2:
The patent changes the structural parameters of allergens by using truncated sequences (70-90% coverage) instead of full-length proteins. This parameter change eliminates the ability of allergens to form their native three-dimensional conformation, thereby preventing IgE binding while maintaining linear epitope recognition by T-cells and B-cells, achieving complete immune response without anaphylaxis risk.
Data Source
Figure 1A~2C
Figure 3A~4B
Figure 5A~7B
AI summary
Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergens of house dust mites Der p 1 and Der p 2. Such peptides while providing all potential T cell epitopes are devoid of the three dimensional structure of the original allergen, therefore reducing their ability to bind IgE. As a result increased amounts of COPs can be administered per injection, therefore reducing both the number of injections and the length of the immunotherapy treatment.